IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Apollon Wealth Management LLC

Apollon Wealth Management LLC lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 26.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 3,578 shares of the medical research company's stock after selling 1,296 shares during the quarter. Apollon Wealth Management LLC's holdings in IQVIA were worth $703,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC increased its stake in IQVIA by 2.3% during the 3rd quarter. Exchange Traded Concepts LLC now owns 4,388 shares of the medical research company's stock worth $1,040,000 after buying an additional 98 shares in the last quarter. Creative Planning increased its stake in IQVIA by 17.8% during the 3rd quarter. Creative Planning now owns 21,013 shares of the medical research company's stock worth $4,980,000 after buying an additional 3,176 shares in the last quarter. Swedbank AB increased its stake in IQVIA by 0.9% during the 3rd quarter. Swedbank AB now owns 91,489 shares of the medical research company's stock worth $21,680,000 after buying an additional 786 shares in the last quarter. Sumitomo Life Insurance Co. increased its stake in IQVIA by 1.4% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 10,068 shares of the medical research company's stock worth $2,386,000 after buying an additional 140 shares in the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd increased its stake in IQVIA by 20.4% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 5,719 shares of the medical research company's stock worth $1,355,000 after buying an additional 968 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Insider Buying and Selling at IQVIA

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of the stock in a transaction on Tuesday, December 3rd. The shares were bought at an average price of $200.58 per share, with a total value of $255,739.50. Following the acquisition, the director now owns 1,275 shares of the company's stock, valued at $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 1.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

IQV has been the subject of several research reports. JPMorgan Chase & Co. cut their price objective on IQVIA from $279.00 to $240.00 and set an "overweight" rating for the company in a research note on Tuesday, November 5th. Barclays decreased their target price on IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft decreased their target price on IQVIA from $270.00 to $265.00 and set a "buy" rating for the company in a report on Friday, November 1st. Stifel Nicolaus cut their price target on IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Finally, Stephens initiated coverage on IQVIA in a research note on Friday, December 20th. They issued an "overweight" rating and a $250.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $251.67.

IQVIA Stock Performance

Shares of NYSE IQV traded down $2.40 during midday trading on Friday, reaching $193.65. 1,527,608 shares of the company were exchanged, compared to its average volume of 1,454,169. The company has a current ratio of 0.84, a quick ratio of 0.81 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The stock has a fifty day simple moving average of $200.41 and a 200 day simple moving average of $218.02. The stock has a market cap of $35.15 billion, a P/E ratio of 25.82, a PEG ratio of 2.25 and a beta of 1.48.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, research analysts forecast that IQVIA Holdings Inc. will post 10.81 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.